These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 26658766

  • 1. Higher Throughput Quantification of Neutralizing Antibody to Herpes Simplex Viruses.
    Blevins TP, Mitchell MC, Korom M, Wang H, Yu Y, Morrison LA, Belshe RB.
    PLoS One; 2015; 10(12):e0144738. PubMed ID: 26658766
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Development of a high-throughput β-Gal-based neutralization assay for quantitation of herpes simplex virus-neutralizing antibodies in human samples.
    Baccari A, Cooney M, Blevins TP, Morrison LA, Larson S, Skoberne M, Belshe RB, Flechtner JB, Long D.
    Vaccine; 2016 Jul 19; 34(33):3901-6. PubMed ID: 27265458
    [Abstract] [Full Text] [Related]

  • 4. A novel method to assay herpes simplex virus neutralizing antibodies using BHKICP6LacZ-5 (ELVIS) cells.
    Ashley RL, Dalessio J, Sekulovich RE.
    Viral Immunol; 1997 Jul 19; 10(4):213-20. PubMed ID: 9473152
    [Abstract] [Full Text] [Related]

  • 5. Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine.
    Awasthi S, Belshe RB, Friedman HM.
    J Infect Dis; 2014 Aug 15; 210(4):571-5. PubMed ID: 24652496
    [Abstract] [Full Text] [Related]

  • 6. Patient-Specific Neutralizing Antibody Responses to Herpes Simplex Virus Are Attributed to Epitopes on gD, gB, or Both and Can Be Type Specific.
    Cairns TM, Huang ZY, Gallagher JR, Lin Y, Lou H, Whitbeck JC, Wald A, Cohen GH, Eisenberg RJ.
    J Virol; 2015 Sep 15; 89(18):9213-31. PubMed ID: 26109729
    [Abstract] [Full Text] [Related]

  • 7. Underestimation of HSV-2 seroprevalence in a high-risk population by microneutralization assay.
    Ashley RL, Dalessio J, Dragavon J, Koutsky LA, Lee FK, Nahmias AJ, Stevens CE, Holmes KK, Corey L.
    Sex Transm Dis; 1993 Sep 15; 20(4):230-5. PubMed ID: 8211541
    [Abstract] [Full Text] [Related]

  • 8. Cell-to-Cell Spread Blocking Activity Is Extremely Limited in the Sera of Herpes Simplex Virus 1 (HSV-1)- and HSV-2-Infected Subjects.
    Criscuolo E, Castelli M, Diotti RA, Amato V, Burioni R, Clementi M, Ambrosi A, Mancini N, Clementi N.
    J Virol; 2019 Jun 01; 93(11):. PubMed ID: 30867302
    [Abstract] [Full Text] [Related]

  • 9. Development of an HSV-1 neutralization test with a glycoprotein D specific antibody for measurement of neutralizing antibody titer in human sera.
    Luo Y, Xiong D, Li HH, Qiu SP, Lin CL, Chen Q, Huang CH, Yuan Q, Zhang J, Xia NS.
    Virol J; 2016 Mar 18; 13():44. PubMed ID: 26987753
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of a novel serology algorithm to detect herpes simplex virus 1 or 2 antibodies.
    Zahariadis G, Severini A.
    Sex Transm Dis; 2010 Nov 18; 37(11):696-9. PubMed ID: 20693937
    [Abstract] [Full Text] [Related]

  • 11. Linear Multiepitope (Glyco)peptides for Type-Specific Serology of Herpes Simplex Virus (HSV) Infections.
    Risinger C, Sørensen KK, Jensen KJ, Olofsson S, Bergström T, Blixt O.
    ACS Infect Dis; 2017 May 12; 3(5):360-367. PubMed ID: 28238255
    [Abstract] [Full Text] [Related]

  • 12. Monoclonal antibody blocking tests for the detection of HSV-1- and HSV-2-specific humoral responses: comparison with western blot assay.
    Slomka MJ, Ashley RL, Cowan FM, Cross A, Brown DW.
    J Virol Methods; 1995 Sep 12; 55(1):27-35. PubMed ID: 8576306
    [Abstract] [Full Text] [Related]

  • 13. A direct quantitative PCR-based measurement of herpes simplex virus susceptibility to antiviral drugs and neutralizing antibodies.
    Virók DP, Eszik I, Mosolygó T, Önder K, Endrész V, Burián K.
    J Virol Methods; 2017 Apr 12; 242():46-52. PubMed ID: 28093274
    [Abstract] [Full Text] [Related]

  • 14. Development of the suppository form of human immunoglobulin preparation with high titers of antibodies to herpes simplex virus types 1 and 2 for the treatment of chronic forms of herpetic disease.
    Lazarenko AA, Alimbarova LM, Mordvintseva EY, Barinsky IF.
    Vopr Virusol; 2017 Apr 12; 62(1):36-41. PubMed ID: 29323845
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Herpes serology for dermatologists.
    Goldman BD.
    Arch Dermatol; 2000 Sep 12; 136(9):1158-61. PubMed ID: 10987876
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. HSV-1 and HSV-2 seroprevalence in the united states among asymptomatic women unaware of any herpes simplex virus infection (Herpevac Trial for Women).
    Schulte JM, Bellamy AR, Hook EW, Bernstein DI, Levin MJ, Leone PA, Sokol-Anderson ML, Ewell MG, Wolff PA, Heineman TC, Belshe RB.
    South Med J; 2014 Feb 12; 107(2):79-84. PubMed ID: 24926671
    [Abstract] [Full Text] [Related]

  • 19. Seroprevalence of HSV-1 and HSV-2 antibodies in Canadian women screened for enrolment in a herpes simplex virus vaccine trial.
    Gorfinkel IS, Aoki F, McNeil S, Dionne M, Shafran SD, Zickler P, Halperin S, Langley J, Bellamy A, Schulte J, Heineman T, Belshe R.
    Int J STD AIDS; 2013 May 12; 24(5):345-9. PubMed ID: 23970700
    [Abstract] [Full Text] [Related]

  • 20. A novel glycoprotein D-specific monoclonal antibody neutralizes herpes simplex virus.
    Du R, Wang L, Xu H, Wang Z, Zhang T, Wang M, Ning Y, Deng F, Hu Z, Wang H, Li Y.
    Antiviral Res; 2017 Nov 12; 147():131-141. PubMed ID: 29061442
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.